Phase 1/2 study of TP-3654, a selective PIM1 kinase inhibitor: Preliminary data showed clinical activity and cytokine reductions in relapsed/refractory myelofibrosis patients Meeting Abstract
| Authors: | Rein, L. A. M.; El Chaer, F.; Yuda, J.; Shimoda, K.; McCloskey, J.; Takami, A.; Haque, T.; Ichii, M.; Shirane, S.; Fukaya, M.; Scandura, J. M.; Bradley, T.; Vachhani, P.; Tabayashi, T.; Green, S.; Cheung, S.; Bose, P.; Khurana, S.; O'Connell, C. L.; Amanam, I.; Ross, D. M.; Kabir, S.; Seki, M.; Wade, M.; Peddagali, V.; Li, Z.; Shah, J.; Rampal, R. K. |
| Abstract Title: | Phase 1/2 study of TP-3654, a selective PIM1 kinase inhibitor: Preliminary data showed clinical activity and cytokine reductions in relapsed/refractory myelofibrosis patients |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 626 |
| Language: | English |
| ACCESSION: | WOS:001159306702139 |
| DOI: | 10.1182/blood-2023-180164 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work